Please, set Additional Menu


About Us

As biopharmaceutical company, we aim to accelerate the development of highly innovative programs with strong therapeutical potential.
ABAXYS represents a new paradigm for Drug Discovery in Neuroscienses.

Our Mission & Vision

Build-up a ‘First-/Best -in-Class’ Innovative Portfolio in Human Neurodegenerative Diseases.

ABAXYS Therapeuthics aims to become a key player and first-choice partner in the area of human CNS diseases. We want to contribute to the development of highly innovative therapeutic solutions for neurodegenerative diseases.

Our approach will significantly reduce the time-to-clinics of efficacious disease modifying therapies for neurodegenerative diseases.

Our Key Approach

Our strategy is based on a business model which uses the local and European top R&D ecosystem to deliver disruptive Preclinical packages contributing to High Value Pharma Therapeutic programs

Hit Identification

With our Data Mining approach, we are able to efficiently identify new Hits.

Lead Optimization

With our Big Data and Simulation approach, we are able to accelerate the Preclinical process (from 3-5 years in only 6 months) by replacing lab, in-vitro, in-vivo experience with in-sillico validation.

Animal Modeling

With our Bio-imaging approach, we do not have to kill the Animal Model to see the impact of a drug. Thus we are able to follow the evolution of the disease, see the impact of a molecule and better predict the efficacy in human.

Our Board

A team profile essential for company needs, combining a long experience and robust know-how in neurosciences discovery, R&D, company creation and financing.

Our Team

  • /
    Javier Garcia-Ladona
    Founder & CEO
  • /
    Guillaume de Viron
  • /
    Olivier Rousseau
    Board Member
  • /
    Yolande Huss
    Co-founder & Board Member
  • /
  • /
  • /
  • /

Our Partners